Search
Research
Brain TumourBrain tumours are the second most common cancer in children (after leukaemia).
Research
Regular exercise improves the well-being of parents of children with cancerMental health benefits of a pedometer-based exercise intervention for parents of children with cancer were identified.
Research
Risk of childhood acute lymphoblastic leukaemia following parental occupational exposure to pesticidesRisk of childhood acute lymphoblastic leukaemia following parental occupational exposure to pesticides.
Research
Interactions between acute lymphoblastic leukemia and bone marrow stromal cells influence response to therapyTo identify links between drug resistance and gene deregulation we used oligonucleotide microarray technology.
People
Timo LassmannFeilman Fellow; Head, Precision Health Research and Head, Computational Biology
Research
Fc-Engineered B7-H3 Antibody with Prolonged Serum Half-Life for Enhanced Cancer TherapyMonoclonal antibodies are revolutionizing the landscape of current cancer treatment, bringing hope to patients with incurable cancers. B7-H3 (CD276) is an attractive therapeutic target for antibody-based therapy due to its low or absent expression in normal tissues and high expression in various types of tumors, including prostate cancer, pancreatic cancer, and high-mortality esophageal squamous cell carcinoma (ESCC). In recent years, various B7-H3-targeting antibodies have been developed for cancer treatment, with a few making their way to clinical trials.
Research
CAR T cells targeting B7H3 demonstrate potent preclinical activity against AML and ESCCT cells engineered to express chimeric antigen receptors (CARs) are a promising modality to treat refractory cancers. CD19 CAR-T therapy has achieved remarkable responses in against B-cell lymphomas, however, challenges persist for acute myeloid leukemia (AML) and solid malignancies. B7H3 is an immune regulatory molecule that is highly expressed in various tumor cells. Its abnormal expression in acute AML and esophageal squamous cell carcinoma (ESCC) is closely related to tumor progression.
Research
It is more “unbalanced” than you thinkSébastien Malinge PhD Laboratory Head, Translational Genomics in Leukaemia, Senior Research Fellow (University of Western Australia), Adjunct Senior
Research
Suppressing recurrence in Sonic Hedgehog subgroup medulloblastoma using the OLIG2 inhibitor CT-179OLIG2-expressing tumor stem cells have been shown to drive recurrence in Sonic Hedgehog (SHH)-subgroup medulloblastoma (MB) and patients urgently need specific therapies to target this tumor cell population.
Research
Anti-metabolite chemotherapy increases LAG-3 expressing tumor-infiltrating lymphocytes which can be targeted by combination immune checkpoint blockadeAntibodies that target immune checkpoints such as cytotoxic T lymphocyte antigen 4, programmed cell death protein/ligand 1 are approved for treatment of multiple cancer types.